Physician profile
Ellen Beth Schaeffer
NPI 1427027671
$541.66
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $182 · 2021: $90.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $131.92 | 2019-2021 | |
| Pharming Healthcare, INC. | $81.55 | 2020 | |
| Genzyme Corporation | $62.05 | 2019-2021 | |
| Glaxosmithkline, LLC. | $56.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $44.75 | 2019-2021 | |
| Pfizer INC. | $28.58 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.91 | 2019 | |
| Csl Behring | $20.33 | 2020 | |
| Alk-Abello, INC | $18.62 | 2021 | |
| Aimmune Therapeutics, INC. | $15.63 | 2020 | |
| Genentech USA, INC. | $14.16 | 2019 | |
| Optinose US, INC. | $14.04 | 2021 | |
| Prugen, INC. Pharmaceuticals | $5.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Schaeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.